Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2972

Sort by

Sort Order Select

Journal Articles

Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor

Saskia B. Wortmann, Johan L. K. Van Hove, Terry G. J. Derks, Nathalie Chevalier, Vijaya Knight, Andreas Koller, Esmee Oussoren, Johannes A. Mayr, Francjan J. van Spronsen, Florian B. Lagler, Sommer Gaughan, Emile Van Schaftingen, Maria Veiga-da-Cunha

Blood (2020) 136 (9): 1033–1043.

https://doi.org/10.1182/blood.2019004465

Published: 2020

Includes: Supplemental data

Journal Articles

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

Blood (2019) 134 (Supplement_1): 605.

https://doi.org/10.1182/blood-2019-125588

Published: 2019

Journal Articles

A Multicenter Study of Romiplostim to Treat Chemotherapy-Induced Thrombocytopenia in Solid Tumors and Lymphoid Malignancies

Hanny Al-Samkari, MD, Aric D Parnes, MD, Katayoon Goodarzi, MD, James I Weitzman, MD, Jean M. Connors, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 389.

https://doi.org/10.1182/blood-2019-123864

Published: 2019

Journal Articles

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Blood (2019) 134 (Supplement_1): 115.

https://doi.org/10.1182/blood-2019-129876

Published: 2019

Journal Articles

Incidence and Time Course of Neutropenia in Patients Treated with Rituximab-Based Therapy for Non-Malignant Immune-Mediated Hematologic Diseases

Luis E Malpica Castillo, MD, Shannon Palmer, MS, Allison Deal, MS, Sheh-Li Chen, PharmD, Anqi Zhu, MS, Stephan Moll, MD

Blood (2019) 134 (Supplement_1): 390.

https://doi.org/10.1182/blood-2019-121343

Published: 2019

Journal Articles

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Angela Dispenzieri, MD, Eftathios Kastritis, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM, Stefan O. Schönland, MD, Kihyun Kim, MD, Vaishali Sanchorawala, MD, Heather J Landau, MD, Fiona Kwok, FRACP,FRCPA,MBBS, Kenshi Suzuki, MD PhD, Raymond L Comenzo, MD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Douglas V. Faller, MD PhD, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 139.

https://doi.org/10.1182/blood-2019-124409

Published: 2019

Journal Articles

Response to Sorafenib in FLT3 /ITD AML Is Depedent on Co-Occurring Mutational Profile

Katherine Tarlock, MD, Jessica A. Pollard, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, Yi-Cheng Wang, Rhonda E. Ries, MA, Jenny L. Smith, MSc, MD, E. Anders Kolb, MD, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 119.

https://doi.org/10.1182/blood-2019-127569

Published: 2019

Journal Articles

Targeting Bcl-2 and CD38 As Part of Personalized HSCT Conditioning Regimen in Chemorefractory Acute Leukemia in Children

Larisa Shelikhova, MD, Rimma Khismatullina, MD, Michael Maschan, MD MSc, Alexey A. Maschan, MD, Irina Kalinina, MD, Elena Kurnikova, Yakov Muzalevsky, Alexey Kazachenok, Dmitriy Pershin, Alexander Popov, MD PhD, Galina Novichkova, MD PhD, Dmitriy Balashov, MD PhD, Daria Shasheleva, MD, Svetlana Kashpor, Evgeny Gluhanyuk

Blood (2019) 134 (Supplement_1): 150.

https://doi.org/10.1182/blood-2019-129765

Published: 2019

Journal Articles

Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients

Blood (2019) 134 (Supplement_1): 4322.

https://doi.org/10.1182/blood-2019-124645

Published: 2019

Journal Articles

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Blood (2019) 134 (Supplement_1): 4563.

https://doi.org/10.1182/blood-2019-125087

Published: 2019

Journal Articles

Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics

Blood (2019) 134 (Supplement_1): 4357.

https://doi.org/10.1182/blood-2019-122657

Published: 2019

Journal Articles

Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort

Henry Wood, MBBS, Katy Sanchez, BSc, MSc, Victoria Potter, MBBS, BSc, FRACP, FRCPA, Austin Kulasekararaj, MD MRCP, FRCPath, Hugues de Lavallade, MD PhD, Deborah Yallop, MBBS, FRCP, FRCPath, PhD, Shireen Kassam, MBBS, FRCPath, PhD, Robin M. Ireland, MBBS, FRCP, FRCPath, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Alan Dunlop, BSc, MSc

Blood (2019) 134 (Supplement_1): 4566.

https://doi.org/10.1182/blood-2019-131711

Published: 2019

Journal Articles

Venetoclax-Based Regimen for Treatment of Patients with Acute Myeloid Leukemia in Community Based Practices

Lisa Y Law, MD, Ryan Stevenson, MD, Gwendolyn Ho, MDMAS, Bijay Nair, MD MPH, Asakura Laura, PharmD, BCOP, BCPS, Antoine Sayegh, MD

Blood (2019) 134 (Supplement_1): 5081.

https://doi.org/10.1182/blood-2019-121816

Published: 2019

Journal Articles

Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study

Donna E Reece, MD, Giovanni Piza Rodriguez, MD, Mariela A Pantoja, PhD MSc, Darrell J White, MD, Christopher P Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Martha L Louzada, MDMSc, Arleigh McCurdy, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger E Tiedemann, MBChB, PhD, Harminder K Paul, MSc, Christine I Chen, MD

Blood (2019) 134 (Supplement_1): 4570.

https://doi.org/10.1182/blood-2019-129357

Published: 2019

Journal Articles

Pilot Study of Oral Realgar-Indigo Naturalis Formula in Pediatric Acute Promyelocyticleukemia: Effectiveness and Population Pharmacokinetics

Li Zhang, Xin-mei Yang, Jing Chen, Lei Hu, Fan Yang, Yue Zhou, Bei-bei Zhao, Wei Zhao, Xiao-fan Zhu, PhD

Blood (2019) 134 (Supplement_1): 5084.

https://doi.org/10.1182/blood-2019-122876

Published: 2019

Journal Articles

Mebendazole Mediates Its Anti-Leukemic Effects By Proteasomal Degradation of GLI Transcription Factors Via Inhibition of HSP70/90-Chaperone Activity in Acute Myeloid Leukemia in a Preclinical and Clinical Setting

Fabian Freisleben, Hauke Stamm, PhD, Jana Muschhammer, Vanessa Thaden, Franziska Modemann, MD, Alexander Krispien, Franziska Brauneck, Jasmin Wellbrock, PhD, Walter Fiedler, MD

Blood (2019) 134 (Supplement_1): 5050.

https://doi.org/10.1182/blood-2019-129973

Published: 2019

Journal Articles

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

David M. Weiner, BA, Nathaniel D. Robinson, MD, Steven M. Bair, MD, Hatcher J. Ballard, BS, Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2019) 134 (Supplement_1): 5250.

https://doi.org/10.1182/blood-2019-128556

Published: 2019

Journal Articles

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Devangi Shah, Jennifer Reichbach Douglas, DNP, APRN, CPHON, Jumana Ashy, Gregory Suhrheinrich, Edward Dela Ziga, MD, Asha B. Pillai, MD, Julio C Barredo, MD, Warren Alperstein, MD

Blood (2019) 134 (Supplement_1): 5680.

https://doi.org/10.1182/blood-2019-125884

Published: 2019

Journal Articles

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Diana Basali, MD, Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Nathaniel Rosko, PharmD, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Hayley Dysert, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Matt Kalaycio, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 5566.

https://doi.org/10.1182/blood-2019-129002

Published: 2019

Journal Articles

On Demand Plerixafor As a Rescue Strategy in Healthy Donors to Achieve Adequate Stem Cells - a Pilot Study from South India

Kishore Kumar, MBBS, MD DM, Kishore Kumar, MBBS, MD DM, Chezhian Subash, FRCPath

Blood (2019) 134 (Supplement_1): 5640.

https://doi.org/10.1182/blood-2019-127045

Published: 2019

NARROW

Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor

Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients

A Multicenter Study of Romiplostim to Treat Chemotherapy-Induced Thrombocytopenia in Solid Tumors and Lymphoid Malignancies

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Incidence and Time Course of Neutropenia in Patients Treated with Rituximab-Based Therapy for Non-Malignant Immune-Mediated Hematologic Diseases

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Response to Sorafenib in FLT3 /ITD AML Is Depedent on Co-Occurring Mutational Profile

Targeting Bcl-2 and CD38 As Part of Personalized HSCT Conditioning Regimen in Chemorefractory Acute Leukemia in Children

Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics

Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort

Venetoclax-Based Regimen for Treatment of Patients with Acute Myeloid Leukemia in Community Based Practices

Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study

Pilot Study of Oral Realgar-Indigo Naturalis Formula in Pediatric Acute Promyelocyticleukemia: Effectiveness and Population Pharmacokinetics

Mebendazole Mediates Its Anti-Leukemic Effects By Proteasomal Degradation of GLI Transcription Factors Via Inhibition of HSP70/90-Chaperone Activity in Acute Myeloid Leukemia in a Preclinical and Clinical Setting

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

A Single Institution Experience of Bortezomib for Gvhd in a Pediatric HSCT Population

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

On Demand Plerixafor As a Rescue Strategy in Healthy Donors to Achieve Adequate Stem Cells - a Pilot Study from South India

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only